ArticleAmerican journal of clinical and experimental urology2025
Decoding the pro-invasive role of SAA2 in renal cell carcinoma: an exploratory study and experimental validation.
Article in American journal of clinical and experimental urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCurrently, there is an urgent need for prognostic prediction models for renal clear cell carcinoma (ccRCC). This study aims to establish a prognostic prediction model based on differential genes associated with TNM staging and validate it through both in vitro and in vivo experiments.
methodThrough the cross-analysis of the differential genes between T1-2 and T3-4 stages, N1 and N2 stages, as well as M0 and M1 stages in ccRCC, a nomogram prognostic model was constructed using multivariate COX regression analysis. Finally, the function of human serum amyloid A2 (SAA2) was verified through in vivo and in vitro experiments.
resultThrough cross-analysis of the differential genes between T1-2 and T3-4 stages, N1 and N2 stages, as well as M0 and M1 stages, 67 genes were identified. Through multivariate COX regression analysis, examination of expression differences between cancerous and normal tissues, and assessment of their impact on prognosis, we have derived a nomogram prognostic prediction model composed of ITPKA, PDIA2, SAA2, SHOX2, TREML3P, and ZIC2. Furthermore, through Transwell migration and invasion assays, EdU proliferation assays, and in vivo experiments, we validated that SAA2 promotes the proliferation, migration, and invasion of ccRCC.
conclusionThe nomogram prognostic prediction model, consisting of ITPKA, PDIA2, SAA2, SHOX2, TREML3P, and ZIC2, is capable of predicting the prognosis of ccRCC patients. Among them, SAA2 promotes the proliferation, migration, and invasion of ccRCC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.